Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882577 | PMC |
| http://dx.doi.org/10.3389/fendo.2025.1492712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The CREscendoing promise of HDAC targeting to limit atherosclerosis.
Immunity
March 2025
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. Electronic address:
The factors that modulate the inflammatory response in atherosclerosis are not well defined. In this issue of Immunity, Asare et al. examine the impact of a cis-regulatory element (CRE) that controls expression of HDAC9 and find that HDAC9-mediated deacetylation of NLRP3 might be the mechanism by which genetic variants in this conserved CRE influence the inflammation associated with human atherosclerosis.
View Article and Find Full Text PDFComment on: Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
J Antimicrob Chemother
March 2025
Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
JAMA
February 2025
Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Importance: Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride into NAD+, resulting in an increase of cellular adenosine triphosphate production.
Objective: To determine the effects of CNM-Au8 on ALS disease progression.
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
JAMA
February 2025
Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Importance: Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.
Objective: To determine the effects of pridopidine, a σ1-receptor agonist, in ALS.
Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al.
J Addict Med
March 2025
Yale School of Medicine, New Haven, CT (ACB, WCB); Yale Program in Addiction Medicine, New Haven, CT (ACB, WCB); and VA Connecticut Healthcare System, West Haven, CT (ACB, WCB).
Opioid use disorder affects millions of people nationally and in 2022 opioid overdose deaths exceeded 80,000. Buprenorphine, a partial mu-opioid receptor agonist, is a gold standard treatment for opioid use disorder, improving withdrawal symptoms and decreasing opioid-related mortality. However, a 2022 Food and Drug Administration warning about oral health problems related to transmucosal formulations has precipitated new research into this medication's potential risks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!